OBJECTIVES: Amyloid senile plaques and tau neurofibrillary tangles are neuropathologic hallmarks of Alzheimer disease, which may be associated with mild cognitive impairment (MCI) or mood and anxiety symptoms years before the dementia diagnosis. To address this issue, the authors obtained positron emission tomography (PET) scans after intravenous injections of 2-(1-{6-[(2-[fluorine-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile (FDDNP), a molecule that binds to amyloid plaques and neurofibrillary tangles, to determine whether symptoms of depression and anxiety in nondemented subjects were associated with increased FDDNP-PET binding values. METHODS: Forty-three middle-aged and elderly volunteers received clinical and FDDNP-PET assessments. Subjects were nondemented--23 of them were diagnosed with MCI and 20 were cognitively normal. Subjects with a diagnosis of major depression or an anxiety disorder were excluded. Correlations between standardized measures of depressive and anxiety symptoms and regional FDDNP binding values were calculated. RESULTS: The MCI and comparison subjects did not differ by the depression and anxiety scores. In the MCI group, depression scores correlated with lateral temporal and trait anxiety scores correlated with posterior cingulate FDDNP binding. In the comparison group, depression scores correlated with medial temporal, and trait anxiety scores correlated with medial temporal and frontal FDDNP binding. DISCUSSION: This is the first report to demonstrate a relationship between the severity of depression and anxiety symptoms and FDDNP binding values in nondemented middle age and older individuals. The results suggest a relationship between relatively mild mood symptoms and biomarkers of cerebral amyloid and tau deposition and vary according to degree of cognitive impairment. The presence of MCI may signify different pathophysiological mechanisms underlying mood and anxiety symptoms.
OBJECTIVES: Amyloid senile plaques and tau neurofibrillary tangles are neuropathologic hallmarks of Alzheimer disease, which may be associated with mild cognitive impairment (MCI) or mood and anxiety symptoms years before the dementia diagnosis. To address this issue, the authors obtained positron emission tomography (PET) scans after intravenous injections of 2-(1-{6-[(2-[fluorine-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile (FDDNP), a molecule that binds to amyloid plaques and neurofibrillary tangles, to determine whether symptoms of depression and anxiety in nondemented subjects were associated with increased FDDNP-PET binding values. METHODS: Forty-three middle-aged and elderly volunteers received clinical and FDDNP-PET assessments. Subjects were nondemented--23 of them were diagnosed with MCI and 20 were cognitively normal. Subjects with a diagnosis of major depression or an anxiety disorder were excluded. Correlations between standardized measures of depressive and anxiety symptoms and regional FDDNP binding values were calculated. RESULTS: The MCI and comparison subjects did not differ by the depression and anxiety scores. In the MCI group, depression scores correlated with lateral temporal and trait anxiety scores correlated with posterior cingulate FDDNP binding. In the comparison group, depression scores correlated with medial temporal, and trait anxiety scores correlated with medial temporal and frontal FDDNP binding. DISCUSSION: This is the first report to demonstrate a relationship between the severity of depression and anxiety symptoms and FDDNP binding values in nondemented middle age and older individuals. The results suggest a relationship between relatively mild mood symptoms and biomarkers of cerebral amyloid and tau deposition and vary according to degree of cognitive impairment. The presence of MCI may signify different pathophysiological mechanisms underlying mood and anxiety symptoms.
Authors: B Winblad; K Palmer; M Kivipelto; V Jelic; L Fratiglioni; L-O Wahlund; A Nordberg; L Bäckman; M Albert; O Almkvist; H Arai; H Basun; K Blennow; M de Leon; C DeCarli; T Erkinjuntti; E Giacobini; C Graff; J Hardy; C Jack; A Jorm; K Ritchie; C van Duijn; P Visser; R C Petersen Journal: J Intern Med Date: 2004-09 Impact factor: 8.989
Authors: A F Jorm; C M van Duijn; V Chandra; L Fratiglioni; A B Graves; A Heyman; E Kokmen; K Kondo; J A Mortimer; W A Rocca Journal: Int J Epidemiol Date: 1991 Impact factor: 7.196
Authors: Meryl A Butters; Ellen M Whyte; Robert D Nebes; Amy E Begley; Mary Amanda Dew; Benoit H Mulsant; Michelle D Zmuda; Rishi Bhalla; Carolyn Cidis Meltzer; Bruce G Pollock; Charles F Reynolds; James T Becker Journal: Arch Gen Psychiatry Date: 2004-06
Authors: Anand Kumar; Vladimir Kepe; Jorge R Barrio; Prabha Siddarth; Vicki Manoukian; Virginia Elderkin-Thompson; Gary W Small Journal: Arch Gen Psychiatry Date: 2011-11
Authors: Sophie E Holmes; Irina Esterlis; Carolyn M Mazure; Yen Ying Lim; David Ames; Stephanie Rainey-Smith; Chris Fowler; Kathryn Ellis; Ralph N Martins; Olivier Salvado; Vincent Doré; Victor L Villemagne; Christopher C Rowe; Simon M Laws; Colin L Masters; Robert H Pietrzak; Paul Maruff Journal: Int J Geriatr Psychiatry Date: 2017-07-24 Impact factor: 3.485
Authors: Matthias Brendel; Oliver Pogarell; Guoming Xiong; Andreas Delker; Peter Bartenstein; Axel Rominger Journal: Eur J Nucl Med Mol Imaging Date: 2015-01-29 Impact factor: 9.236
Authors: P Aisen; J Touchon; R Amariglio; S Andrieu; R Bateman; J Breitner; M Donohue; B Dunn; R Doody; N Fox; S Gauthier; M Grundman; S Hendrix; C Ho; M Isaac; R Raman; P Rosenberg; R Schindler; L Schneider; R Sperling; P Tariot; K Welsh-Bohmer; M Weiner; B Vellas Journal: J Prev Alzheimers Dis Date: 2017
Authors: L Chouliaras; A S R Sierksma; G Kenis; J Prickaerts; M A M Lemmens; I Brasnjevic; E L van Donkelaar; P Martinez-Martinez; M Losen; M H De Baets; N Kholod; F van Leeuwen; P R Hof; J van Os; H W M Steinbusch; D L A van den Hove; B P F Rutten Journal: Int J Alzheimers Dis Date: 2010-10-05